Strategic Expansion Balt is expanding from neurovascular into peripheral vascular interventions, presenting cross-selling opportunities to customers already using their neurovascular devices.

Financing Momentum With substantial funding and a recent €355 million financing round, Balt has capital to accelerate product development, capacity expansion, and regional market growth, enabling new sales and partnerships.

Regulatory Milestone Premarket Approval of the Squid liquid embolic agent signals a broader product suite and potential for new procurement cycles and multi-device case builds with hospital systems.

Global Footprint Operating across 16 sites with global reach, Balt offers scalable supply and regional support, allowing strategic multi-country pilots and adoption by large health networks.

Clinical Collaboration Longstanding physician collaboration and a broad portfolio for ischemic/hemorrhagic stroke create opportunities to upsell integrated solutions, training, and value-based partnerships with providers.